[HTML][HTML] Managing potential drug interactions of Nirmatrelvir/Ritonavir in COVID‐19 patients: a perspective from an Israeli Cross‐Sector Collaboration
S Guy‐Alfandary, S Zhurat, M Berlin… - Clinical …, 2022 - ncbi.nlm.nih.gov
In this perspective, we highlight major clinical pharmacologyrelated issues encountered
since the rapid introduction of nirmatrelvir/ritonavir in Israel. We describe the rationale for the …
since the rapid introduction of nirmatrelvir/ritonavir in Israel. We describe the rationale for the …
Pharmacokinetics/pharmacodynamics of antiviral agents used to treat SARS-CoV-2 and their potential interaction with drugs and other supportive measures: a …
M Zeitlinger, BCP Koch, R Bruggemann… - Clinical …, 2020 - Springer
There is an urgent need to identify optimal antiviral therapies for COVID-19 caused by SARS-
CoV-2. We have conducted a rapid and comprehensive review of relevant pharmacological …
CoV-2. We have conducted a rapid and comprehensive review of relevant pharmacological …
Use of antivirals in SARS-CoV-2 infection. Critical review of the role of remdesivir
The aim of this report is to review the literature and shed light on the uncertainties
surrounding the use of antiviral agents in general and remdesivir in COVID-19 patients. This …
surrounding the use of antiviral agents in general and remdesivir in COVID-19 patients. This …
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients–authors' response
M Sun, H Lai, Z Zhang, L Ge - Journal of Antimicrobial …, 2023 - academic.oup.com
We thank Drs Kow, Ramachandram and Hasan for their interest in our review and their
knowledgeable comments. 1 We agree with your thoughtful view that the most important …
knowledgeable comments. 1 We agree with your thoughtful view that the most important …
Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials
Background To summarise specific adverse effects of remdesivir, hydroxychloroquine and
lopinavir/ritonavir in patients with COVID-19. Methods We searched 32 databases through …
lopinavir/ritonavir in patients with COVID-19. Methods We searched 32 databases through …
Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19
J Buxeraud, S Faure, É Fougere - Actualités pharmaceutiques, 2022 - Elsevier
Nirmatrelvir-ritonavir (Paxlovid®), a treatment for Covid-19 The nirmatrelvir-ritonavir
(Paxlovid®) is a treatment against Covid-19 available in pharmacies since February 4, 2022 …
(Paxlovid®) is a treatment against Covid-19 available in pharmacies since February 4, 2022 …
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo …
Y Wang, F Zhou, D Zhang, J Zhao, R Du, Y Hu… - Trials, 2020 - Springer
Abstract Background Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus
(later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China …
(later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China …
A review of the preclinical and clinical efficacy of remdesivir, hydroxychloroquine, and lopinavir-ritonavir treatments against COVID-19
In December of 2019, an outbreak of a novel coronavirus flared in Wuhan, the capital city of
the Hubei Province, China. The pathogen has been identified as a novel enveloped RNA …
the Hubei Province, China. The pathogen has been identified as a novel enveloped RNA …
[HTML][HTML] Effectiveness and adverse events of nirmatrelvir/ritonavir versus molnupiravir for COVID-19 in outpatient setting: multicenter prospective observational study
JJ Park, H Kim, YK Kim, SS Lee, E Jung… - Journal of Korean …, 2023 - ncbi.nlm.nih.gov
Background In this study, we aimed to compare the effectiveness and adverse reactions of
nirmatrelvir/ritonavir and molnupiravir in high-risk outpatients with coronavirus disease 2019 …
nirmatrelvir/ritonavir and molnupiravir in high-risk outpatients with coronavirus disease 2019 …
Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial
F Ader, M Bouscambert-Duchamp, M Hites… - Medrxiv, 2022 - medrxiv.org
Background The antiviral efficacy of remdesivir is still controversial. We aimed at evaluating
its clinical effectiveness in hospitalised patients with COVID-19, with indication of oxygen …
its clinical effectiveness in hospitalised patients with COVID-19, with indication of oxygen …